Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

This phase IIa trial compares the safety and effect of temozolomide combined with survivin long peptide vaccine (SurVaxM) to temozolomide alone in patients with neuroendocrine tumors (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and is growing, spreading or getting worse (progressing). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Survivin, a protein, is expressed in 50% of patients that have neuroen

Trial Details

NCT ID

NCT06202066

Phase

PHASE2

Sponsor

Roswell Park Cancer Institute

Status

RECRUITING

Cancer Type

Pancreatic Neuroendocrine Pancreatic Cancer

Interventions

Biospecimen Collection
Computed Tomography
Incomplete Freund''s Adjuvant
Magnetic Resonance Imaging
Sargramostim
SVN53-67/M57-KLH Peptide Vaccine

Locations (sample)

Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

Age ≥ 18 years of age
Have a Karnofsky performance status ≥ 80 or Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (i.e. the patient must be able to care…
Measurable, pathologically confirmed diagnosis of neuroendocrine tumor of gastrointestinal, pancreatic, or thoracic origin with ki67\>20% (well-dif…
Patients must have documented radiographic progression, determined as clinically significant by the treating provider, within the last twelve month…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Neuroendocrine Pancreatic Cancer Trials on Trialify →